Clinical trials: Myeloid
Periodontitis
Analysis of Soluble TREM (Triggering Receptor Expressed on Myeloid Cells)-1 and -2 in Crevicular Fluid and Associated Bacterial Flora in Patients Affected by Periodontitis
Etiopathology of periodontitis is complex and various risk factors are known : Bacterial factors: major risk factor. Although the presence of periodontopathogen bacteria is necessary for the onset of periodontitis, these…
- Trial name
- TREM (NCT02873949)
- Testing
- Crevicular samples (1-10µl), Saliva samples (1ml), Etiologic treatment
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Acute Myeloid Leukemia (AML)
IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients
This leukemia is characterized by a poor prognosis for most patients, as they have a high relapse rate despite aggressive treatment with chemotherapy agents and allogeneic bone marrow transplantation.
- Trial name
- NCT03204838
- Testing
- IDH mutation test performed at diagnosis
- Where
- Mexico
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hospital General de Mexico
Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation
A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant
The purpose of this study was to confirm a safe dose and schedule as well as the preliminary efficacy of siremadlin alone, and in combination with donor lymphocyte infusion (DLI), in adult participants with Acute Myeloid Leukemia…
- Trial name
- NCT05447663
- Testing
- Siremadlin
- Where
- 6 sites in Germany, Italy and 1 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
Phase Ib, open-label, dose-escalation clinical trial to evaluate the best-tolerated doses in Acute Myeloid Leukaemia (AML) relapsed or refractory to chemotherapy. This open-label, nonrandomized trial will comprise 2 stages.
- Trial name
- NCT03197714
- Testing
- OPB-111077
- Where
- 6 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Hospital Universitario 12 de Octubre
Acute Myeloid Leukemia
Observational Study of Spatio-Temporal Patterns of New Cases of Acute Myeloid Leukemia
Published data regarding the temporal pattern of AML are scarce and old. The greater knowledge of these neoplasias has made that their classification has been remarkable modified.
- Trial name
- NCT03433521
- Where
- Spain
- Volunteers
- 15,000 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Chronic Myeloid Leukemia, Chronic Phase
Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
This phase 2 single-arm study aims to demonstrate the efficacy of strong cytochrome inhibition with ketoconazole to reduce dasatinib dosage for adults with chronic myelogenous leukemia.
- Trial name
- NCT05638763
- Testing
- Dasatinib Pill, Ketoconazole Pill
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Leukemia, Myelodysplastic Syndromes
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of dolastatin 10 in treating patients who have refractory…
- Trial name
- NCT00003693
- Testing
- Dolastatin 10
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloid Leukemia
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
To evaluate the safety and efficacy of subcutaneous administration of omacetaxine mepesuccinate (HHT) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have failed prior imatinib therapy…
- Trial name
- NCT00375219
- Testing
- Omacetaxine mepesuccinate
- Where
- 32 sites in United States, Canada and 8 more
- Volunteers
- 103 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes
The hypothesis of this study is that 5-aza and lenalidomide act synergistically in MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q.
- Trial name
- AZALE (NCT00923234)
- Testing
- Azacitidine, Lenalidomide
- Where
- 4 sites in Germany
- Sponsor
- Technische Universität Dresden
Acute Myeloid Leukemia
Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition
The treatment of older patients with acute myeloid leukemia that is secondary to previous myelodysplastic syndrome, myeloproliferative neoplasm, or prior cytotoxic exposure remains unsatisfactory.
- Trial name
- LAM-BDD (NCT03284593)
- Testing
- intensive chemotherapy, Azacitidine
- Where
- 2 sites in France
- Volunteers
- 199 people
- Sponsor
- University Hospital, Toulouse
Myeloid Neoplasm
The Myeloid Neoplasms Biology and Outcome Project
The Myeloid Neoplasms Biology and Outcome Project (MyBOP) aims to establish a registry study for patients with myeloid neoplasms.
- Trial name
- MyBOP (NCT05074316)
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- University Hospital Heidelberg
Leukemia, Myelodysplastic Syndromes
Decitabine in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of decitabine in treating patients with myelodysplastic…
- Trial name
- NCT00003361
- Testing
- decitabine
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myelogenous Leukemia
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Our goal is to demonstrate that 50mg of dasatinib is as effective as the full dose to induce molecular response as first line therapy in CML.
- Trial name
- NCT03216070
- Testing
- Dasatinib 50 MG
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Acute Myeloid Leukemia
Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics
Severe neutropenia caused by venetoclax,a B-cell lymphoma-2(BCL-2) inhibitor, is the main cause of venetoclax tapering, drug discontinuation, and treatment delay.
- Trial name
- NCT06295029
- Volunteers
- 200 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Acute Myeloid Leukemia
A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML
This study evaluates the effect of pembrolizumab on the duration of remission in acute myeloid leukemia. Pembrolizumab is given after complete remission is obtained in those with AML at least 60 years old who are not candidates…
- Trial name
- NCT02708641
- Testing
- pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Michael Boyiadzis
Leukemia, Myelogenous, Acute, Myelodysplastic Syndromes
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS
This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503 (combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML and MDS.
- Trial name
- NCT01085656
- Testing
- OXi4503
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Florida
Chronic Myeloid Leukemia (CML)
Second STOP After Pioglitazone Priming in CML Patients
Single-center study, prospective, phase II trial. The study objectives are : To assess safety and pharmacokinetics of the combination of PIO and TKI in CML subjects who experience a loss of MMR following a first TKI…
- Trial name
- PIO2STOP (NCT02889003)
- Testing
- Pioglitazone + TKI
- Where
- 6 sites in France
- Volunteers
- 26 people
- Sponsor
- Versailles Hospital
Acute Myeloid Leukemia
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
This phase I trial tests safety, side effects and best dose of iadademstat with azacitidine and venetoclax for the treatment of patients with acute myeloid leukemia (AML) who have not received treatment (treatment naive).
- Trial name
- NCT06514261
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Phase Chronic Myelogenous Leukemia
Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor
The aim of the study is to assesse the levels of various biomarkers, specifically interleukin (IL)-6, platelet-derived microparticles (PDMPs), 11, 12 soluble vascular cell adhesion molecule 1 (sVCAM-1), transforming growth factor…
- Trial name
- NCT03907670
- Volunteers
- 45 people
- Sponsor
- Assiut University
Acute Lymphoblastic Leukemia, Myeloblastic Leukemia
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and calcineurin inhibitor in children and young adults with hematoloblastosis after myeloablative…
- Conditions
- Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma
- Trial name
- NCT05515029
- Testing
- GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor
- Where
- Russia
- Volunteers
- 56 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.